Advertisement


Antonio Marra, MD, on Metastatic Breast Cancer: Patterns of Genomic Instability and Their Effect on Treatment

ESMO Congress 2022

Advertisement

Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses a mutational signature analysis that reveals patterns of genomic instability linked to resistance to endocrine therapy with or without CDK4/6 inhibition in patients with estrogen receptor–positive/HER2-negative metastatic breast cancer (Abstract 210O).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The study we presented at this meeting was focused on the mutational signature analysis of breast cancers. We used the genomic data collected from a clinical sequencing program at Memorial Sloan Kettering, and we studied over 4,000 breast cancer, studying mutational signatures, that are mutational processes that shape the genomes of this cancer. In breast cancer, we have three main mutational processes and mutational signatures that are HRD, APOBEC, and clock. Our work will mainly focus on APOBEC and HRD that are the two main mutational signatures that cause genomic instability. We firstly try to identify which are the main settings where these signatures are rich, and we find that both HRD and APOBEC are rich in the metastatic samples of the ER-positive HER2-negative subtype. We then evaluated the clinical and pathologic features of these tumors, and we found the enrichment for specific pattern including lobular phenotype and tumor with high tumor mutational burden. From a treatment perspective, we then evaluated the role of the signature on the response to specific treatments and we found something really interesting, because these two signature were both associated with a lower progression-free survival for patient treated on first-line with endocrine therapy with or without CDK4/6 inhibitor, suggesting that genomic instability caused by these two mutation processes is associated with the reduced benefit from standard treatments. We then focus the last part of our work on studying the genomic mechanism of APOBEC mutagenesis in breast cancer and we found some very strong genetic association including enrichment for variant-specific genes like CDH1, PIK3CA, and most importantly also, some genes are associated with endocrine-resistance like NF1 or PTEN. We finally did a very strong analysis on the association within PIK3CA variants and APOBEC mutagenesis found a specific region in tumors that have multiple PIK3CA mutations and this may have some clinical indication considering that breast cancer with multiple PIK3CA mutations seems to have a better response to PIK3C-alpha-selective inhibition. In conclusion, our study shows that genomic stability is a marker of lower benefit on endocrine therapy and CDK4/6 inhibition, and most importantly, we may have in the future new treatment targeting this mutational process that can open to advancement in treatments and open new opportunities for our patients.

Related Videos

Pancreatic Cancer

Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel

Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).

Solid Tumors

Bernd Kasper, MD, PhD, on Desmoid Tumors: Results on Nirogacestat vs Placebo

Bernd Kasper, MD, PhD, of Germany’s Mannheim Cancer Center, discusses phase III data from the DeFi trial, the largest study conducted to date for patients with desmoid tumors. The trial showed that the gamma secretase inhibitor nirogacestat demonstrated improvements in all primary and secondary efficacy endpoints. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and, occasionally, mortality in patients (Abstract LBA2).

Prostate Cancer

Rahul Aggarwal, MD, on Prostate Cancer: Phase III Data on Apalutamide and Androgen Deprivation in Relapsed Disease

Rahul Aggarwal, MD, of the University of California, San Francisco, discusses recent data from the PRESTO study, which showed that apalutamide plus androgen-deprivation therapy (ADT) for 12 months significantly prolonged PSA progression-free survival compared with ADT alone in patients with biochemically recurrent prostate cancer. These results provide support for the intensification of ADT in this setting. (Abstract LBA63).

Gynecologic Cancers
Immunotherapy

Ana Oaknin, MD, PhD, on Cervical Cancer: Safety and Efficacy Results With Nivolumab and Ipilimumab

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses findings from the CheckMate 358 trial, which showed that chemotherapy-free immunotherapy with nivolumab alone or in combination with ipilimumab may provide durable tumor regression with manageable toxicity in patients with recurrent or metastatic cervical cancer, regardless of tumor PD-L1 expression (Abstract 520MO).

 

Bladder Cancer
Immunotherapy

Jonathan E. Rosenberg, MD, on Urothelial Cancer: Results From EV-103, Cohort K on Enfortumab Vedotin and Pembrolizumab

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses recent findings on the safety and antitumor activity of enfortumab vedotin-ejfv given intravenously as monotherapy or in combination with pembrolizumab to previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (Abstract LBA73).

Advertisement

Advertisement



Advertisement